Treat-to-target  ||| S:0 E:16 ||| JJ
in  ||| S:16 E:19 ||| IN
rheumatoid  ||| S:19 E:30 ||| JJ
arthritis ||| S:30 E:39 ||| NN
:  ||| S:39 E:41 ||| :
clinical  ||| S:41 E:50 ||| JJ
and  ||| S:50 E:54 ||| CC
pharmacoeconomic  ||| S:54 E:71 ||| JJ
considerations ||| S:71 E:85 ||| NNS
.  ||| S:85 E:87 ||| .
Introduction  ||| S:87 E:101 ||| UH
